Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19

Mayuko Ishiwari; Yuki Togashi; Hiroyuki Takoi; Ryota Kikuchi; Yuta Kono; Shinji Abe

doi:10.1002/rcr2.679

Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19

Respirol Case Rep. 2020 Nov 1;8(9):e00679. doi: 10.1002/rcr2.679. eCollection 2020 Dec.

Authors

Mayuko Ishiwari¹, Yuki Togashi¹, Hiroyuki Takoi¹, Ryota Kikuchi¹, Yuta Kono¹, Shinji Abe¹

Affiliation

¹ Department of Respiratory Medicine Tokyo Medical University Hospital Tokyo Japan.

Abstract

A 69-year-old man with a history of type 2 diabetes and high blood pressure was diagnosed with coronavirus disease 2019 (COVID-19). He had hyperferritinaemia and respiratory failure. Despite the initiation of favipiravir and high-dose corticosteroid and ceftriaxone, his respiratory failure progressed and serum ferritin levels increased. After polymyxin B-immobilized fibre column direct haemoperfusion (PMX-DHP) therapy, there was improvement of the respiratory failure and hyperferritinaemia. We report the first case of COVID-19-induced hyperferritinaemia and severe respiratory failure successfully treated by PMX-DHP.

Keywords: COVID‐19; PMX‐DHP; hyperferritinaemia.

Publication types

Case Reports